US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

438.71

-18.1242-3.97%

Number of Gainers:- -

Number of Losers:4

Number of Flat:- -

PE:- -

High:456.83

Open:456.83

Low:438.23

Close:456.83

Volume:11.93M

Turnover:205.98M

Market Cap:9.90B

Float Cap:9.28B

Loading ...

Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today

Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today

Editas Medicine EVP, Chief Medical Officer Daniel Ory Files Initial Beneficial Ownership Statement

Editas Grants New CMO Daniel Ory Stock Options for 950,000 Shares at USD 3.03 Each

Press Release: Editas Medicine Reports Inducement Grants to New Chief Medical Officer

JonesTrading Remains a Buy on Beam Therapeutics (BEAM)

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints

Beam Therapeutics falls -12.7%

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Intellia Rises After FDA Grants Fast-Track Status to Its Treatment for Rare Disease

CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Intellia Therapeutics Shares up 4.9% Premarket After FDA Accepts to Fast-Track Co's Treatment for a Rare Swelling Disorder

THOMSON REUTERS

Intellia Therapeutics announces FDA acceptance of lonvo-z BLA

Intellia Says FDA Accepts Lonvo-Z BLA for Hereditary Angioedema, Grants Priority Review

Intellia Therapeutics, - FDA Accepts Bla for Lonvo-Z and Grants Priority Review with Pdufa Date March 10, 2027

THOMSON REUTERS

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-Z) for Hereditary Angioedema (Hae)

THOMSON REUTERS

Intellia Therapeutics, - FDA not Planning to Hold Advisory Committee for Lonvo-Z Application

THOMSON REUTERS

Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Editas Medicine Appoints Dan Ory, M.d., as Chief Medical Officer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":438.70538,"timestamp":1788983999999,"preClose":456.8296,"halted":0,"volume":11927107,"delay":0,"changeRate":-0.039674,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-18.124207,"latestTime":"09-09 16:00:00 EDT","open":456.8296,"high":456.8296,"low":438.22684,"amount":205978144.00333,"amplitude":0.040721,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.804619,"peRate":-10.111273,"turnoverRate":0.027272,"increases":0,"decrements":4,"flats":0,"marketCap":9901696448,"floatMarketCap":9284059872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":456.8296,"amplitude":0.040721,"preClose":456.8296,"low":438.22684,"pbRate":"2.804619","latestPrice":438.70538,"volume":11927107,"delay":0,"open":456.8296,"prevYearClose":431.70972,"prevWeekClose":475.3505,"prevMonthClose":478.4385,"prevQuarterClose":517.3469,"fiveDayClose":475.6278,"twentyDayClose":448.903,"sixtyDayClose":438.0567,"secType":"PLATE","market":"US","turnoverRate":0.027272,"peRate":-10.111273,"marketCap":9901696448,"floatMarketCap":9284059872,"timestamp":1788983999999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":0,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666155540","title":"Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2666155540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666155540?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:10","pubTimestamp":1788999021,"startTime":"0","endTime":"0","summary":"20:05 EDT Cathie Wood’s ARK Investment buys 204K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-204k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-204k-shares-of-intellia-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKW","ARKQ","ARKX","BK4588","SARK","ARKK","ARKF","LU1861558580.USD","BK4139","BK4544","BK4585","BK4556","NTLA","BK4535","ARKG","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555446","title":"Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555446","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555446?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:10","pubTimestamp":1788999015,"startTime":"0","endTime":"0","summary":"20:05 EDT Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics (BEAM) today Published first on TheFly – the ultimate source for real-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-271k-shares-of-beam-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-271k-shares-of-beam-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4539","LU1861559042.SGD","ARKG","SARK","ARKK","BK4505","BK4556","BK4535","ARKF","ARKX","LENZ","BK4611","BK4544","BK4007","BK4585","ARKQ","LU1861558580.USD","BEAM","ARKW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666453032","title":"Editas Medicine EVP, Chief Medical Officer Daniel Ory Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666453032","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666453032?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:25","pubTimestamp":1788985521,"startTime":"0","endTime":"0","summary":"Editas Medicine EVP, Chief Medical Officer Daniel Ory files initial beneficial ownership statementEditas Medicine filed a Form 3 naming Daniel Ory as EVP, chief medical officer, dated Sept. 8, 2026.Di","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL2MS6p2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666383535","title":"Editas Grants New CMO Daniel Ory Stock Options for 950,000 Shares at USD 3.03 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2666383535","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666383535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:02","pubTimestamp":1788958923,"startTime":"0","endTime":"0","summary":"Editas grants new CMO Daniel Ory stock options for 950,000 shares at USD 3.03 eachEditas Medicine granted new Chief Medical Officer Daniel Ory stock options for 950,000 shares, priced at USD 3.03 per ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDLbmgnFk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU0314104364.USD","BCDF","IE00BGHQF748.EUR","SG9999014039.USD","IE00BQXX3D17.EUR","LU2210150020.SGD","EDIT","IE00BN0W2T93.GBP","IE00BQXX3F31.USD","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","BK4556","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4585","BK4112","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014021.USD","IE00BQXX3C00.GBP","NDAQ","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533041","title":"Press Release: Editas Medicine Reports Inducement Grants to New Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533041","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533041?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:00","pubTimestamp":1788958800,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4556","EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666747538","title":"JonesTrading Remains a Buy on Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666747538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666747538?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956156,"startTime":"0","endTime":"0","summary":"In a report released today, Boris Peaker from JonesTrading reiterated a Buy rating on Beam Therapeutics, with a price target of $35.00. According t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-beam-therapeutics-beam-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4535","LU1861558580.USD","BK4588","BK4585","BEAM","LU1861559042.SGD","BK4556","BK4611","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666769587","title":"Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666769587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666769587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952232,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Collegium Pharmaceutical (COLL), Revolution Medicine...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IE00B4R5TH58.HKD","LU0889565916.HKD","COLL","BK4588","XBI","BK4556","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4007","LU0029874061.USD","BK4535","BK4137","CANC","IDNA","IE00BFTCPJ56.SGD","IE0009355771.USD","NTLA","RVMD","LU1861559042.SGD","IE00BJJMRZ35.SGD","LABU","XLV","BBH","PTH","HCSG","IE0009354923.USD","LU1861558580.USD","BK4585","LU0320765992.SGD","BK4581","LU0109394709.USD","IE0002141913.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372629","title":"Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372629","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372629?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:24","pubTimestamp":1788895440,"startTime":"0","endTime":"0","summary":"Beam Therapeutics shares were down after the company shared updated data for its trial of a treatment for the genetic condition alpha-1 antitrypsin deficiency.Shares declined 9% to $26.88 on Tuesday. The stock is roughly flat this year.In a Phase 1/2 trial evaluating BEAM-302 for AATD, the treatment was well tolerated with an acceptable safety profile, the company said.The updated results were not worse than previous data, but were not numerically better, either, Evercore ISI analysts led by Cory Kasimov said.At the 12-month mark, total alpha-1 antitrypsin in treated patients came down to 13.5 uM  to 14.4 uM, compared with 16.1 uM at the nine-month mark. The treatment is supposed to increase alpha-1 antitrypsin, a protein made by the liver.About 41% of patients experienced adverse events, with the most common being mild-to-moderate infusion-related reactions.Based on the feedback from the Food and Drug Administration, Beam plans to pursue an accelerated approval pathway for the treatme","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4611","BK4505","BEAM","BK4556","LENZ","BK4535","BK4585","BK4588","BK4539","LU1861559042.SGD","LU1861558580.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376646","title":"Beam Therapeutics falls -12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376646?lang=en_us&edition=fundamental","pubTime":"2026-09-08 22:06","pubTimestamp":1788876363,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) is down -12.7%, or -$3.78 to $25.88. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-falls-12-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-falls-12-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","BK4535","BK4007","LU1861559042.SGD","BK4585","BK4588","BK4505","BK4539","LU1861558580.USD","BK4139","LENZ","BK4556","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665752763","title":"U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665752763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665752763?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:57","pubTimestamp":1788875845,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, NovartisSeptember 8 (Reuters)-Wall Street's main indexes were mixed at open on Tuesday as fresh hostilities in the Middle East pushed oil price","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL6N4500HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0985489474.SGD","LU0868494617.USD","BEC","LU1291159041.SGD","LU2362541273.HKD","RGTZ","BK4504","QTUP","BK4102","IOYY","VTWG","BK4541","LU0154245673.USD","PBE","LU1988902786.USD","BK4532","BK4597","BEG","LU2244417387.USD","TBXU","IBAT","LU1791710582.SGD","RGTC","UNFI","BHVN","BK4556","SEI","IE0002141913.USD","AMGN","IONS","SIMS","BK4182","LU2098885051.SGD","LU0432979614.USD","LU2506951958.HKD","LU0211331839.USD","LU0077335932.USD","IE00BJT1NW94.SGD","WQTM","LU0109394709.USD","BK4591","CHRW","ABM","LU0138981039.USD","LU0128526141.USD","LU1093756325.SGD","BK4534","LU2249611893.SGD","SRPT","IE00B66KJ199.SGD","LU2506952170.USD","LU2242649171.HKD","LU1489326972.SGD","LU2087625088.SGD","LU0122379950.USD","ALV","SG9999001176.USD","VCLN","BK4121","BK4585","LU1064131342.USD","SHAK","LU0823414551.USD","UPGR","BK4168","LU0345769128.USD","ICLN","SG9999001440.SGD","BBH","BIB","LU2242652126.USD","BK4082","ILMN","LU0187121727.USD","IE00B2B36J28.USD","LU0444971666.USD","LU2264538146.SGD","IE00B19Z4B17.USD","IONC","LU0823416689.USD","LU1989771016.USD","IBBQ","LU1989772923.USD","LU0208291251.USD","LU2357305700.SGD","LU1989764748.USD","BK4131","LU2265009873.SGD","IE0031619046.USD","IE0034235188.USD","LU2491050071.SGD","LU2491050154.USD","LU2362540622.SGD","IONQ","LU0238689110.USD","LU1548497426.USD","LU2242646821.SGD","LU2357125470.USD","LU1804176565.USD","IONX","LU0070302665.USD","IE00BJJMRZ35.SGD","LU1989764664.SGD","BK4566","LU1878469433.USD","SGML","LU0950375773.USD","BK4120","LU2543165471.USD","LU1093756168.USD","LU1815336760.USD","LU1366192091.USD","BK4602","BK4548","LU2491049909.HKD","FRNW","LU0068578508.USD","LU2362541513.USD","SRPU","WATS","BK4567","LU1720051108.HKD","LU1153585028.USD","LU1861558580.USD","XES","DYN","ROIV","IE00BFTCPJ56.SGD","LU1642822529.SGD","LU2324357040.USD","BK4578","IE00B7SZL793.SGD","LU1571399168.USD","BK4505","PPH","BE","LU0957808578.USD","LU0444973449.USD","LU1791710400.SGD","BK4179","LU2294711713.HKD","LU1720051017.SGD","HYDR","PUL","BK4170","LU0267386448.USD","SGXZ57979304.SGD","NVS","BK4141","LU0433182093.SGD","BK4209","LU0225283273.USD","LU0029874061.USD","RGYY","LU0289739699.SGD","LU0476273544.USD","LU0320765992.SGD","LU0823417653.USD","RGTX","LU0353189763.USD","BK4007","LU0823414478.USD","SMOG","BK4139","BK4124","LU0011850046.USD","CNRG","CTEC","LU0528227936.USD","LU0154245756.USD","LU0345769631.USD","LU1983299246.USD","LU0889565916.HKD","LU2112291526.USD","LU1303367103.USD","GNMX","IE00B4R5TH58.HKD","MEDX","LU2506951792.HKD","BK4588","EGGY","04332","BEX","LU0114720955.EUR","LU0878866978.SGD","LU1061106388.HKD","BK4599","OIH","P","LU2089984988.USD","LU0320765489.SGD","IE0009354923.USD","RGTU","CQTM","LU1718418525.SGD","ZAP","LU0353189680.USD","LU1023059063.AUD","SG9999001176.SGD","LU2506952097.USD","LU0058720904.USD","PHVS","PJP","SG9999013999.USD","LU0048584097.USD","LU0251132253.USD","LU0266013472.USD","LU2506951875.HKD","BK4535","LU1057294990.SGD","BK4533","LU0882574055.USD","GNOM","IONZ","NTLA","IBB","LU1861559042.SGD","LU1989772840.SGD","IONL","BK4581","LU2468319806.SGD","PTH","USNG","BSX","RGTI","BEZ","LU0823417737.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665785593","title":"Intellia Rises After FDA Grants Fast-Track Status to Its Treatment for Rare Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2665785593","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665785593?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:30","pubTimestamp":1788870612,"startTime":"0","endTime":"0","summary":"BUZZ-Intellia rises after FDA grants fast-track status to its treatment for rare disease** Shares of Intellia TherapeuticsNTLA.Orise 6.4% to $13.55 premarket** Co says the U.S. FDA  accepted its appli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","LU1861558580.USD","NTLA","BK4585","BK4139","BK4535","LU1861559042.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378198","title":"CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378198","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378198?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:30","pubTimestamp":1788870600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, Sept.  08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th A","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357662/0/en/crispr-therapeutics-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LU1861559042.SGD","BK4137","ARKG","SYNB","BK4139","BK4588","XLV","BK4556","BK4581","LU0128526141.USD","BK4585","CRSP","LU0029874061.USD","HCSG","LU1861558580.USD","LABU","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665202923","title":"Intellia Therapeutics Shares up 4.9% Premarket After FDA Accepts to Fast-Track Co's Treatment for a Rare Swelling Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2665202923","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665202923?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:17","pubTimestamp":1788869828,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500Y6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1861559042.SGD","BK4585","LU1861558580.USD","NTLA","BK4535","BK4588","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320747","title":"Intellia Therapeutics announces FDA acceptance of lonvo-z BLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320747","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320747?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:11","pubTimestamp":1788869463,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) announced the FDA has accepted the biologics license application for lonvo-z and granted the BLA Priority Review with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-announces-fda-acceptance-of-lonvo-z-bla-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-announces-fda-acceptance-of-lonvo-z-bla-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","BK4139","BK4588","NTLA","BK4556","BK4585","BK4535","LU1861558580.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665693320","title":"Intellia Says FDA Accepts Lonvo-Z BLA for Hereditary Angioedema, Grants Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2665693320","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665693320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:04","pubTimestamp":1788869080,"startTime":"0","endTime":"0","summary":"Intellia says FDA accepts lonvo-z BLA for hereditary angioedema, grants priority reviewFDA accepted Intellia’s BLA for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, granting Priority Revie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1VgXtP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","LU1861558580.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU0314104364.USD","LU1861559042.SGD","NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","BK4585","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4588","BK4112","NTLA","IE00BQXX3F31.USD","BK4556","BK4139","LU2210150020.SGD","BCDF","BK4535","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320611","title":"Intellia Therapeutics, - FDA Accepts Bla for Lonvo-Z and Grants Priority Review with Pdufa Date March 10, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320611?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1WGSXV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","LU1861559042.SGD","BK4585","BK4588","NTLA","BK4556","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320349","title":"Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-Z) for Hereditary Angioedema (Hae)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320349?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1WGSXV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1861558580.USD","BK4588","BK4535","NTLA","BK4556","BK4585","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665232061","title":"Intellia Therapeutics, - FDA not Planning to Hold Advisory Committee for Lonvo-Z Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2665232061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665232061?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:00","pubTimestamp":1788868804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA1WGSXV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4535","NTLA","BK4588","BK4139","BK4556","LU1861558580.USD","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732264","title":"Press Release: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732264","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732264?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865260,"startTime":"0","endTime":"0","summary":"Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical developmentAppointment strengthens executive leadership team as Editas","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAP","ASCI","BK4139","WDNA","IE00B7SZL793.SGD","HELX","IE00B19Z4B17.USD","IDNA","BK4556","IE0031619046.USD","GNMX","SYNB","BK4214","BK4588","EDIT","BK4585","IE00B66KJ199.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322562","title":"Editas Medicine Appoints Dan Ory, M.d., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322562?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA8HHBTT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}